Vor Bio's Telitacicept IgAN Data Published in NEJM, but Structural Risks Remain

What happened

Vor Bio announced the publication of interim results from the TELIGAN Phase 3 trial of telitacicept in IgA nephropathy in the New England Journal of Medicine, showing a 55% relative reduction in proteinuria versus placebo at 39 weeks with stable eGFR. This adds to the growing body of positive China data supporting telitacicept's efficacy across multiple autoimmune indications, but the trial was sponsored by RemeGen and does not directly de-risk Vor's global development program. Our DeepValue report highlights that Vor remains a single-asset biotech with a compressed patent tail (composition-of-matter expiry around 2028), heavy warrant overhang, and a history of dilutive financings totaling over $250M in recent months. The gMG Phase 3 results in 1H27 are the key catalyst, and this IgAN publication does not alter that timeline or address the competitive threat from AstraZeneca, Regeneron, and FcRn inhibitors. Therefore, while the NEJM publication provides a near-term sentiment boost, it does not change the fundamental risk/reward calculus favoring a wait stance.

Implication

The NEJM publication validates telitacicept's efficacy in IgAN, strengthening the asset's credibility and potentially supporting a broader label argument. However, our master report underscores that Vor faces a compressed patent tail (2028 expiry), heavy warrant overhang, and a capital structure that has already seen >$250M in recent equity raises. The gMG Phase 3 results (1H27) remain the pivotal catalyst, and IgAN data do not directly impact that timeline or de-risk the global regulatory path. Moreover, competitive dynamics from AstraZeneca and Regeneron in gMG remain intense, and Vor lacks the commercial infrastructure of larger rivals. Thus, while the news may provide a short-term trading lift, the risk of further dilution and execution slippage keeps us on the sidelines. Our attractive entry remains at $10, and we need to see disciplined capital allocation and enrollment progress before upgrading.

Thesis delta

The NEJM publication incrementally validates telitacicept's broad autoimmune potential but does not shift the core thesis that Vor remains a high-risk, single-asset story with significant dilution and competitive overhang. The primary catalysts (gMG data, Sjögren's initiation, capital discipline) remain unchanged. We maintain a 'Wait' stance until either price resets closer to cash-adjusted downside or execution materially exceeds expectations.